No annual revenue total was found in PASSAGE BIO, INC.'s SEC filings.
Passage Bio, Inc. (PASG) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Jun 30, 2026 it held $24.2 million in cash and investments and $24.0 million in total debt.
Revenue
—
Net income (TTM)
$-36.11M
+36.5% vs year-ago TTM
Operating cash flow (TTM)
$-33.50M
+7.1% vs year-ago TTM
Free cash flow
$-47.99M
EPS (TTM)
$-11.31
+37.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
3.21M
-94.8% vs prior year
Net cash
$145,000
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PASG (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Philadelphia, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1787297
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$49.3M | -$70.4M | -$108.4M | -$138.4M | -$185.7M |
| Net income | -$45.5M | -$64.8M | -$102.1M | -$136.1M | -$185.4M |
| Diluted EPS | -$14.35 | -$21.04 | -$1.86 | -$2.50 | -$3.48 |
| Operating cash flow | -$31.5M | -$48.0M | -$78.3M | -$118.2M | -$126.9M |
| Free cash flow | — | -$48.0M | — | — | — |
| Total assets | $62.3M | $102.4M | $150.5M | $243.5M | $355.1M |
| Total liabilities | $43.5M | $41.2M | $39.3M | $42.2M | $36.4M |
| Stockholders' equity | $18.8M | $61.3M | $111.3M | $201.4M | $318.7M |
| Cash and investments | $46.3M | $76.8M | $114.3M | $189.6M | $315.8M |
| Total debt | $24.0M | $25.5M | $26.3M | $27.1M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 3, 2026 | Sep 2, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, Unregistered share sale, Change in control, Officer or director change, Regulation FD disclosure, Other events
|
Jun 24, 2026 | Jun 23, 2026 |
| 8-K |
Current report
Agreement ended
|
May 27, 2026 | May 21, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 26, 2026 | May 19, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
All 442 Passage Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.